Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Novo Nordisk Files Once-Weekly Basal Insulin in Japan
Novo Nordisk Pharma said on August 10 that it has filed a new drug application in Japan for its once-weekly insulin icodec for the treatment of “insulin therapy-indicated diabetes.” Insulin icodec is the world’s first once-weekly basal insulin analog, which…
To read the full story
Related Article
BUSINESS
- Tracleer Generics Add Digital Ulcer Prevention Use
March 26, 2026
- Generic Makers Win Pediatric Dosing Approval for Azilva Copies
March 26, 2026
- Nippon Kayaku’s Humira Biosimilar Adds Pediatric UC Use
March 26, 2026
- Kyorin Inks Sirturo Commercial Deal with J&J in Japan
March 26, 2026
- Ono Sets Course for Growth Beyond Opdivo Patent Cliff
March 25, 2026
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…